Ivacaftor : five‐year outcomes in the West of Scotland cystic fibrosis population

Al‐Din, Yasmin and Dryden, Carol and MacGregor, Gordon and Young, David and Coelho, Cristina (2023) Ivacaftor : five‐year outcomes in the West of Scotland cystic fibrosis population. The Clinical Respiratory Journal, 17 (5). pp. 473-477. ISSN 1752-699X (https://doi.org/10.1111/crj.13602)

[thumbnail of Al-Din-etal-CRJ-2023-Ivacaftor-five-year-outcomes-in-the-West-of-Scotland]
Text. Filename: Al_Din_etal_CRJ_2023_Ivacaftor_five_year_outcomes_in_the_West_of_Scotland.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (304kB)| Preview


Introduction: Ivacaftor has shown to be effective in patients with cystic fibrosis (CF) with a G551D mutation. Objectives: This work aims to evaluate ivacaftor's effectiveness and safety in the real world, over 5 years, in the West of Scotland CF population. Methods: We evaluated ivacaftor's effect on pulmonary function, body mass index (BMI), hospital bed occupancy, and adverse effects in patients ≥6 years with at least one G551D mutation. Results: Statistically significant increases from baseline were observed in mean per cent predicted forced expiratory volume in 1 s (FEV1) at year 1 (which was maintained at years 2 and 5) and BMI over 5 years in our adolescent/adult cohort. Improvements were observed in per cent predicted FEV1 within the paediatric cohort with a suggestion of a plateau effect. The increase in paediatric BMI z‐score was nonstatistically significant. There was a reduction in the number of pulmonary exacerbations requiring intravenous antibiotics and hospital bed occupancy. Ivacaftor was well tolerated. Conclusion: Ivacaftor was effective in our population.